There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alimera (ALIM), G1 Therapeutics Inc (GTHX) and Genocea Biosciences (GNCA) with bullish sentiments.
Alimera (ALIM)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Alimera, with a price target of $2.50. The company’s shares closed yesterday at $0.98.
Selvaraju said:
“As we roll forward the DCF analysis, our estimated enterprise value of the firm has increased from $200M to $228M. Excluding $38M debt and $30M preferred stock, the estimated market value of the firm is $160M. Assuming 70M shares outstanding at the end of 3Q19, this translates to a per share value of approximately $2.50.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -13.9% and a 21.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on Alimera is a Strong Buy with an average price target of $2.75.
See today’s analyst top recommended stocks >>
G1 Therapeutics Inc (GTHX)
H.C. Wainwright analyst Edward White maintained a Buy rating on G1 Therapeutics Inc today and set a price target of $75. The company’s shares closed yesterday at $39.93.
According to TipRanks.com, White is a 5-star analyst with an average return of 14.2% and a 44.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $77.25 average price target.
Genocea Biosciences (GNCA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences today and set a price target of $5. The company’s shares closed yesterday at $0.62, close to its 52-week low of $0.49.
Pantginis commented:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -18.2% and a 26.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Currently, the analyst consensus on Genocea Biosciences is a Moderate Buy with an average price target of $3.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
